51 results about "Joints inflammation" patented technology

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention discloses a lactobacillus rhamnosus capable of improving joint inflammation and promoting bone health, a metagen and application of the lactobacillus rhamnosus, the lactobacillus rhamnosus is lactobacillus rhamnosus BN02, the lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center on November 27, 2023, and the preservation number is CGMCC No.29133. The lactobacillus rhamnosus can be used for improving joint inflammation and promoting bone health. The lactobacillus rhamnosus BN02 can reduce the number of gram-negative bacteria in intestinal tracts of arthritis patients, increase the synthesis amount of bone collagen, and is beneficial to promoting absorption of vitamin C by the intestinal tracts, improving joint inflammation and promoting bone health.

The invention discloses an oral joint protection composition containing ergothioneine and a preparation method thereof, and relates to the technical field of joint protection compositions. The oral joint protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.05 to 5 parts of the ergothioneine, 20 to 50 parts of glucosamine salt, 10 to 30 parts of chondroitin sulfate, 2 to 10 parts of curcumin, 30 to 70 parts of a diluent, 1 to 10 parts of an adhesive, 0.5 to 5 parts of a lubricant, 2 to 10 parts of a disintegrating agent and 0.1 to 0.5 part of an antioxidant stabilizer. Through synergistic compatibility of active ingredients such as ergothioneine, curcumin and the like, a multi-dimensional action network of oxidation resistance, inflammation resistance and cartilage metabolism regulation is formed, the inhibition effect on joint inflammation is remarkably improved, and the limitation of a single ingredient is broken through.

The invention belongs to the technical field of biological medicine, and particularly relates to a KGN-loaded nano vesicle, a soluble microneedle and a preparation method and application of the KGN-loaded nano vesicle and the soluble microneedle. The preparation method comprises the following steps: loading KGN into mesenchymal stem cell membrane nano vesicles by adopting a co-extrusion method to obtain KGN-atNVs; and then integrating the KGN-NVs into the dissolvable microneedle by adopting a micro-molding method to obtain the KGN-NVs-loaded dissolvable microneedle. The soluble microneedle loaded with the KGN-atNVs can effectively reduce expression of inflammatory factors such as IL-1beta and TNF-alpha, reduce joint inflammation, protect a cartilage structure, promote cartilage repair and improve joint functions. According to the KGNN-NV delivery system based on the dissolvable microneedle, the immune regulation and drug delivery advantages of the mesenchymal stem cell membrane nanovesicles and the percutaneous delivery characteristic of the dissolvable microneedle can be synergistically exerted, and an innovative and practical solution is provided for clinical treatment of arthritis.

The invention discloses a low-temperature plasma-based portable joint inflammation accurate therapeutic apparatus, and relates to the technical field of arthritis treatment, the low-temperature plasma-based portable joint inflammation accurate therapeutic apparatus comprises a shell, the lower end of the shell is fixedly connected with a first magnetic type interface, the interior of the shell is fixedly connected with a graphene heat-conducting fin, the front end of the graphene heat-conducting fin is fixedly connected with a circuit board, and the circuit board is fixedly connected with a power supply. A plasma generator, a battery, an ozone neutralization module, a communication module and a control chip are fixedly installed at the front end of the circuit board, through a magnetic attraction structure of the first magnetic attraction type interface and the second magnetic attraction type interface, in cooperation with mechanical positioning of the positioning block and the butt joint groove, rapid replacement of the treatment probe is achieved, and by replacing probes of different forms, the treatment efficiency is improved. The probe can adapt to complex joint contours, a miniature ultrasonic transducer is integrated in the probe, tissue gaps can be temporarily expanded by means of the cavitation effect of ultrasonic waves, the penetration depth of plasma active particles is increased, and the probe effectively acts on deep synovial tissues.

The invention relates to the technical field of microbiology, in particular to application of Eubacterium rectum to preparation of a preparation for relieving rheumatoid arthritis. It is found for the first time that Eubacterium rectum can improve joint inflammation and bone destruction of mice by adjusting immune tolerance, and the Eubacterium rectum is applied to development of microbial preparations containing Eubacterium rectum so as to improve intestinal flora of rheumatoid arthritis patients, so that the effects of adjusting immunity and relieving rheumatoid arthritis conditions are achieved.

The invention belongs to the technical field of medicines, and particularly relates to application of BAY-069 in preparation of a medicine for treating rheumatoid arthritis. Through metabonomics research, the inventor finds that the metabolic enzyme BCAT2 is remarkably highly expressed in synovial tissues of an active-stage RA patient and is relatively low in expression in synovial tissues of a remission-stage RA patient. The high expression of the metabolic enzyme BCAT2 is closely related to synovitis and bone destruction. The BAY-069 as a BCAT2 inhibitor can significantly reduce the score of joint inflammation, reduce synovitis and bone destruction, and effectively reduce bone loss. The invention provides an innovative RA metabolism targeted treatment strategy which has high safety and strong targeting property.

The invention belongs to the technical field of medicine technology, particularly relates to application of isochlorogenic acid C in medicine for treating inflammation, and provides novel application of isochlorogenic acid C in preparation of anti-inflammation medicine, and particularly has a good inhibition effect on abnormal behaviors such as invasion of synovial fibroblasts and secretion of inflammatory factors. Isochlorogenic acid C is provided as an effective medicine component for treating arthritis, and the main action mechanism is to inhibit invasion of RA-FLS and secretion of IL-6 so as to relieve clinical symptoms; the innovation of the invention lies in that: the invention provides treatment of inflammation based on isochlorogenic acid C, and through application of a specific dosage, joint inflammation of patients can be effectively relieved and joint functions can be improved.

The invention discloses application of targeting CD36 in treatment of rheumatoid arthritis, and relates to the technical field of biological materials, and the technical key points are as follows: the CD36 is an effective target spot for treating the rheumatoid arthritis, the content of the CD36 in the body of an RA patient is reduced, and RA-FLS proliferation and release of inflammatory factors can be inhibited; a new molecular mechanism that CD36 participates in RA-FLS activation by regulating fatty acid metabolism is found, CD36 is a new target for relieving RA joint inflammation and injury, and a new treatment direction is provided for clinical treatment of RA.

The invention relates to the technical field of functional food, in particular to an electrolyte composition beneficial to joint injury repair after exercise and a preparation method of the electrolyte composition. The electrolyte composition is mainly prepared from the following raw materials in parts by mass: 0.1 to 2 percent of N-acetylglucosamine, 0.05 to 0.5 percent of cartilage extract, 0.05 to 0.5 percent of enzymolysis bone meal, 0.01 to 0.05 percent of milk mineral salt, 0.1 to 1 percent of collagen peptide, 0.01 to 0.3 percent of vitamin and 0.03 to 0.3 percent of electrolyte. The nano hydrated milk mineral salt is adopted, the absorption efficiency of elements such as calcium and phosphorus in a body is improved, and the electrolyte composition is prepared by combining components such as N-acetylglucosamine and the cartilage extract, so that joint inflammation and cartilage injury caused by exercise are effectively improved while water and electrolyte are supplemented, and the activity of joints and exercises is improved. The electrolyte composition is good in taste, high in stability and suitable for joint protection and nutrition supplement after exercise.

The present invention relates to the field of nutraceuticals, specifically to a synergistic bioactive composition designed to improve joint health. This composition comprises Palmitoylethanolamide (PEA) and Cucumis sativus, aimed at reducing joint pain and protecting cartilage. It addresses the complex pain components of osteoarthritis, including both nociceptive pain, which stems from ongoing joint inflammation and tissue damage, and neuropathic pain, which indicates nerve damage. This nutraceutical composition provides a novel solution for mitigating the debilitating effects of osteoarthritis through oral administration, utilizing pharmaceutically acceptable excipients to ensure efficacy and safety.

The present disclosure provides improved methods, therapeutic regimens, and systems for treating a disease associated with a pituitary malignancy in a subject, such as treating Cushing Syndrome, or treating one or more symptoms of Cushing Syndrome in subjects, through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods. The present disclosure also relates to compositions for use and methods in treating synovial inflammation in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression. The present disclosure also relates to compositions for use and methods in treating degenerative joint disease, joint inflammation, and manifestations thereof in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression.

The invention relates to a piezoelectric nano-material with ultrasonic responsiveness, which is a PVP (Polyvinyl Pyrrolidone) modified bismuth oxyiodate nano-sheet, the particle size is 100-200 nm, and a surface electric field can be generated under the ultrasonic action. The piezoelectric nano material can hyperpolarize the potential of a T cell membrane and inhibit an ion channel Kv1.3 regulated and controlled by the membrane potential, so that Th17 cell differentiation is reduced, and joint inflammation is relieved; the piezoelectric nano material is further prepared into a joint injection preparation, and the joint injection preparation can be combined with ultrasonic irradiation to be applied to treatment of rheumatoid arthritis. According to the invention, the piezoelectric nano material is successfully applied to immune microenvironment regulation and control of rheumatoid arthritis for the first time, and the product and technology blank in the field of'precisely regulating and controlling immune cell functions by using physical signals to treat autoimmune diseases' is filled.

Composition for improving inflammation in osteoarthritis, characterized in that the composition comprises the following components, measured in parts by weight: 1 to 5 parts by weight of N-acetylglucosamine and 0.1 to 2 parts by weight of calcium element in a calcium source.

A method for detecting inflammation in a body joint of a subject, including: providing at least one thermal image of at least one body joint, wherein the at least one thermal image includes indications of temperature of the at least one body joint; marking at least one region of interest (ROI) in the at least one thermal image, wherein the marked ROI is a region in the at least one thermal image which includes pixels representing elevated temperatures and less elevated temperatures in the at least one thermal image; extracting values of one or more parameters of distribution of the temperature indications in the at least marked ROI; detecting inflammation in the body joint based on the extracted values.

The invention discloses a multivalent triangular DNA origami delivery system as well as a preparation method and application thereof, which can be used as a novel method for treating osteoarthritis, and is particularly suitable for patients with cartilage degeneration and joint inflammation caused by age, obesity, joint reuse, sport injury or genetic factors and the like. Specific siRNAs (small interfering RNAs) are delivered by the use of multivalent triangular DNA origami. According to the scheme, the expression of inflammation and degeneration related genes, such as Stat3, MMP3 and MMP13, in cartilage cells in joints can be specifically inhibited, so that the inflammatory response is relieved, cartilage decomposition is inhibited, and repair and regeneration of cartilage tissues are promoted. The invention provides a method for treating osteoarthritis, which has the advantages of strong targeting property, small side effect and obvious curative effect, is suitable for clinical treatment and basic medical research, and has wide application prospect.

The utility model discloses a rheumatism immune joint heating device, which relates to the technical field of rheumatism immunization and comprises a device body, telescopic columns are fixedly connected to the inner bottom walls of the edges of the two sides of the device body, a heating physiotherapy assembly is fixedly connected to the tops of the telescopic columns, and a protection assembly is connected to the inner side wall of the heating physiotherapy assembly in a limiting manner. Massage beads are fixedly connected to the outer surface of the top of the device body; through the arrangement of the telescopic column and the massage balls, the effects of accurate adjustment and comfort are achieved when a person operates the device, the flexible telescopic characteristic of the telescopic column enables the heating device to be tightly attached to unique curved surfaces of different patients and different joint parts, the heating device can adapt to individual differences of different patients, it is guaranteed that heat evenly covers all the joints, and the heating effect is improved. No local overheating or insufficient heating condition exists, the joints are always in the best heating state, an ideal environment is created for relieving joint inflammation, the massage beads can apply moderate pressure to muscular tissue around the joints, and the comfort degree is improved.

This invention relates to the field of traditional Chinese medicine (TCM) technology, specifically to a TCM composition for treating rheumatoid arthritis and its application. The TCM composition comprises the following raw materials: mulberry twigs, Gentiana macrophylla, Phellodendron chinense, earthworm, stir-fried Arctium lappa, Achyranthes bidentata, stir-fried Bombyx mori, Lonicera japonica, and Spatholobus suberectus. This TCM composition can reduce arthritis scores and paw volume in rats with rheumatoid arthritis, reduce the spleen coefficient in rats with rheumatoid arthritis, significantly reduce TNF-α, IL-6, and IL-1β in rat serum, improve joint inflammation, and has no toxic side effects. This indicates that the TCM composition for treating rheumatoid arthritis in this application can alleviate symptoms in patients with rheumatoid arthritis, exert its anti-inflammatory and analgesic effects, and thus treat rheumatoid arthritis.

A composition is provided comprising an effective amount of a combination of gamma linolenic acid (GLA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). The composition comprises about 5% w / w to about 25% w / w GLA, and about 5% w / w to about 25% w / w of a mixture of DHA and EPA. Methods of modulating fatty acid profiles or treating an inflammatory condition in a horse include administering an effective amount of the composition to the horse. The inflammatory conditions capable of being treated include gastric ulcers, airway inflammation, joint inflammation, or combinations thereof.

This invention discloses a nutritional composition and preparation method for improving joint health in senior pets. The nutritional composition comprises: N-acetylglucosamine, chondroitin sulfate, methanesulfonylmethane, unsaponifiable avocado and soybean extract, hyaluronic acid, curcumin microcapsule powder, and high-concentration fish oil. This invention uses a lipid / polysaccharide bilayer microcapsule structure to encapsulate curcumin and fish oil, and prepares the product through low-temperature homogenization, spray drying, and granulation processes. The composition of this invention works synergistically through multiple pathways, simultaneously exerting effects on three key levels: anti-inflammation, lubrication, and cartilage repair. It can significantly inhibit joint inflammation, improve joint lubrication, and promote cartilage repair. This invention solves the problems of existing pet joint products, such as single pathways of action, low stability and bioavailability of lipid-soluble active ingredients, and lack of overall formulation optimization tailored to the characteristics of aging pets. It is suitable for daily joint health maintenance or adjunctive treatment in middle-aged and senior dogs and cats.

The invention discloses a nano polymer for specific targeted degradation of COX-2, a preparation method and application, and belongs to the technical field of biological medicines. The nano polymer comprises polyethylene glycol methacrylate with ROS responsiveness, a functional monomer for targeted degradation of COX-2, and a ligand structure monomer for recruiting E3 ligase. The invention proves that compared with a single COX-2 inhibitor, the prepared PKP-NP nano polymer has more excellent treatment performance. The problem of hydrophobicity of a traditional PROTAC medicine is solved, COX-2 protein is specifically and continuously degraded, cartilage cell apoptosis is inhibited, and cartilage tissue damage is repaired; the composition can accurately gather in an articular cavity by virtue of inflammation microenvironment response, prolong in-vivo retention time, relieve joint inflammation and repair cartilage injury, and has no obvious side effect. An efficient, safe and lasting scheme is provided for osteoarthritis treatment, and a new idea for clinical treatment is developed.

This invention relates to a compound gel for treating joint inflammation based on a modified ancient Chinese medicine formula, belonging to the fields of pharmaceutical preparations and traditional Chinese medicine. The compound gel consists of active ingredient extracts, a poloxamer thermosensitive gel matrix, a penetration enhancer, a humectant, and deionized water. The active ingredient extracts are obtained from *Terminalia chebula*, *Amla emblica*, lavender, wild watermelon, *Artemisia annua*, and chamomile through ultrasonic-microwave coupling extraction. Using ultrasonic-microwave coupling extraction combined with a low-temperature drying process, small-molecule active ingredients are obtained. A body temperature-responsive gel is constructed based on poloxamer 407 / 188, achieving in-situ phase transition on the skin surface and stable sustained release over 6-8 hours, significantly improving transdermal absorption. The gel is combined with an integrated medication container and biomimetic protective gear to form a synergistic drug delivery system, achieving closed-loop controlled release, leak-proof design, and motion adaptation. This gel is non-irritating and non-allergenic, suitable for topical treatment of osteoarthritis, rheumatoid arthritis, and soft tissue injuries caused by cold and dampness in high-altitude regions.

The invention discloses a pharmaceutical composition for preventing and treating joint inflammation / relieving pain and a preparation method thereof. The pharmaceutical composition comprises the following components: 1, glucosamine sulfate 2KCL (99%), 2, chondroitin sulfate, 3, methylsulfonylmethane (MSM), 4, type II collagen, 5, a morinda officinalis root extract, 6, a herba epimedii extract, 7, a sambucus williamsii extract, 8, a rhizoma drynariae extract, 9, a turmeric root extract, 10, hyaluronic acid and 11, chitosan. The pharmaceutical composition can be prepared into tablets, capsules, dispersible tablets, chewable tablets, effervescent tablets, buccal tablets and other oral preparations. The composition has the effect of preventing and relieving knee joint inflammation / pain.

The present invention refers to an oligonucleotide comprising 15 to 22 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with pre-mRNA of mixed lineage kinase domain like pseudokinase (MLKL) derived from SEQ ID NO.1289 (GRCh38.p 14: 16:74671855-74700960) or mRNA of MLKL derived from SEQ ID NO.1290 (RefSeq ID NM_152649.4). The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The pharmaceutical composition and the oligonucleotide are for use in a method of preventing and / or treating a hyperproliferative disorder, an inflammatory or autoimmune disorder, neurodegenerative disease, a neurological disorder, cardiovascular, metabolic disorder, renal disorder, liver disorder, lung disorder, skin disorder, ocular disorder, disorder of the gastro-intestinal tract, joint inflammation, organ malfunction after organ transplantation, fibrotic disorder and a combination thereof inflammatory disease, cancer, an ophthalmic disease, an autoimmune disorder and / or an immune disorder.

The invention discloses a methacrylic acid hyaluronic acid hydrogel microsphere wrapped by a macrophage membrane and application, and relates to the technical field of drug synthesis, the key points of the technical scheme are as follows: the methacrylic acid hyaluronic acid hydrogel microsphere EMMatHMs wrapped by the macrophage membrane can efficiently neutralize key proinflammatory factors, the proinflammatory factors comprise TNF-alpha and IL-1beta, therefore, the joint inflammation is relieved. The compound has good curative effect and biocompatibility in an OA model, and especially has effects in the aspects of regulating macrophage polarization, inhibiting cartilage cell hypertrophy and neutralizing proinflammatory factors. By targeting key links in OA pathogenesis, the EMM-at-HMs not only can significantly reduce inflammation, but also has the potential of delaying the disease progress, and provides a new strategy with breakthrough significance for treatment of OA.

The present disclosure is directed to peptide-polymer conjugates, and to their use in treating intra-articular diseases or disorders.

The invention belongs to the technical field of construction of disease animal models, and discloses a construction method of a psoriatic arthritis animal model, which adopts zymosan mannan and a complete Freund's adjuvant to jointly induce psoriatic arthritis for modeling. According to the invention, the zymosan mannan and the complete Freund's adjuvant are used for combined induction, so that the typical pathological manifestation of psoriatic arthritis can be stably simulated, and particularly, the model is superior to the existing animal model in the aspect of simultaneously inducing joint inflammation and psoriasis-like skin lesion, and is closer to the pathological characteristics of clinical patients.

The invention relates to the field of bone health, and discloses a PQQ and bone collagen peptide synergistic composition for preventing osteoporosis and a process, the composition comprises the following components by mass: 0.5-2.0 parts of pyrroloquinoline quinone disodium salt; 20 to 40 parts of bone collagen peptide; 15 to 30 parts of enzymolysis fish bone meal; 3 to 8 parts of sodium hyaluronate; 0.5 to 2.0 parts of quercetin; 0.05 to 0.15 part of vitamin K2-MK7 (vitamin K2-MK7) 10 to 20 parts of seaweed calcium; 5 to 15 parts of a pH response type liposome carrier; 5 to 15 parts of isomaltooligosacharide; 3 to 8 parts of calcium gluconate; and 0.5 to 3.0 parts of a compound nutrition enhancer. Through multiple innovative technical schemes, the bone mineral density and collagenous fibers are remarkably improved, the bioavailability of calcium is greatly improved, the anti-inflammatory effect is enhanced, the directional conveying efficiency of calcium is optimized, osteoporosis is effectively prevented, and joint inflammation is effectively improved.